Clinical Assessment of Protopic® Ointment in Deep Partial-Thickness Burns

Status Recruiting

Clinical Trial Summary

There is currently no standard treatment to prevent burn depth conversion in partial-thickness burns. Conversion into deeper wounds is associated with higher complications and morbidity. The most common theory attributes this depth conversion to the prolonged inflammatory response that occurs after burn injury. Therefore, the investigators propose testing the safety and efficacy of tacrolimus ointment (an immunosuppressive agent) in patients with deep partial-thickness burns.

Clinical Trial Description

Patients who sustain burn injuries are some of the most complex patients to care for, often requiring a multidisciplinary team of providers specialized in burn pathophysiology. While many facets of burn care must be accounted for including fluid management, nutrition, respiratory status, immunologic and cardiovascular function, innovation in the treatment for deep partial thickness burns is of paramount importance. Burn depth conversion is a phenomenon where superficial partial-thickness burns spontaneously convert into deep partial-thickness or full-thickness burns, which are associated with higher complications and morbidity. The most common theory attributes this depth conversion to the prolonged inflammatory response that occurs after burn injury. Excess inflammation worsens the injury through various mechanisms, including cytokine production, delayed inflammatory cell apoptosis, and reactive oxidative species production. Protopic® (tacrolimus) Ointment is a macrolide immunosuppressant and a calcineurin inhibitor. Tacrolimus inhibits T-lymphocyte activation, a key cell in the body's immune response. A prolonged inflammatory response is theorized to contribute to a worse recovery outcome in partial- to full-thickness burns. Therefore, tacrolimus possesses properties that could slow the acute inflammatory response and potentially improve clinical outcomes in deep partial-thickness burns. There has yet to be a clinical study to investigate the use of tacrolimus in burn treatment. However, our group recently published an animal study that found a significant reduction in burn depth using tacrolimus topically (White-Dzuro et al. Burns 2022). This study is a randomized clinical trial of the usage of tacrolimus ointment for the treatment of deep partial-thickness burns with comprehensive assessments of healing and functional outcomes. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05856994
Study type	Interventional
Source	Vanderbilt University Medical Center
Contact	Wesley Thayer, MD, PhD
Phone	6159360160
Email	wesley.thayer@vumc.org
Status	Recruiting
Phase	Phase 1
Start date	August 1, 2023
Completion date	June 1, 2025

View Details

See also
Status	Clinical Trial	Phase
Withdrawn	`NCT02241941` - Evaluation of Single-dose Pharmacokinetics of Intravenous Daptomycin in Patients With Thermal Injury	Phase 4
Completed	`NCT02210208` - A Soft Silicone Wound Contact Layer Containing Silver in the Treatment of Skin Grafts in Surgical Burn Patients.	N/A
Completed	`NCT05063409` - Transfusion Ratio of Fresh Frozen Plasma (FFP) to Packed Red Blood Cell (PRBC) During Burn Excision and Grafting	N/A
Completed	`NCT03730688` - Non-invasive Limb Compartment Pressure Measurement	N/A
Recruiting	`NCT04368117` - STAT: Standard Therapy Plus Active Therapy	N/A
Terminated	`NCT01773083` - Trial of Nebulized Heparin Versus Placebo for Inhalation Trauma	Phase 3
Completed	`NCT02092701` - Effects of Cholecalciferol Supplementation on Bone Health and Muscle Strength in Adults During Post-burn Period	N/A
Completed	`NCT02145130` - Phase I Study for Autologous Dermal Substitutes and Dermo-epidermal Skin Substitutes for Treatment of Skin Defects	Phase 1
Completed	`NCT01618630` - Amino Acid Supplementation in Recovery From Severe Burns	N/A
Recruiting	`NCT05876442` - Efficacy of EPSW Plus HILT on Carpal Tunnel Syndrome Post Burn Injury	N/A
Completed	`NCT04417439` - The Effect of Acute Phase Treatment Approaches on Creatine Kinase and the Musculoskeletal System in Different Types of Burns
Completed	`NCT02417818` - Cutaneous Microcirculation After Plasma Therapy	N/A
Completed	`NCT02417805` - Cutaneous Microcirculation After Remote Ischemic Preconditioning	N/A
Completed	`NCT02417779` - Cutaneous Microcirculation After Extracorporeal Shock Wave Therapy	N/A
Not yet recruiting	`NCT06263296` - Smartphone Assisted Self-management Education for Adult Burn Patient at Aftercare	N/A
Completed	`NCT01404026` - Effects of Transcranial Direct Current Stimulation (tDCS) on Neuropathic Symptoms Due to Burn Injury	N/A
Completed	`NCT03204669` - Trace Element Repletion Following Severe Burn Injury	N/A
Recruiting	`NCT04947449` - Potential Benefits of Laser Treatment on Skin Blood Flow and Sweating in Burn Survivors
Not yet recruiting	`NCT05532488` - Inulin in Burn-induced Insulin Resistance	N/A
Recruiting	`NCT02189538` - Effect of n-3 PUFA From Fish in Enteral Nutrition of Major Burn Patients	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.